Paper591982
Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
Caraceni TA and 3 others. J Neurol Neurosurg Psychiatry, 1977. Cited by 28 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease. Papers, record 591982. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/591982
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benserazide | Major topic |
| Bromocriptine | Major topic |
| Hydrazines | Major topic |
| Levodopa | Major topic |
| Parkinson Disease | Major topic |
| Aged | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 319,421 | [Treatment of parkinsonian syndromes by bromocriptin]. | Nouv Presse Med | 1977 | https://conductscience.org/library/papers/319421 | PubMed |
| 2 | 989,885 | Treatment of parkinson's disease with bromocriptine. | N Engl J Med | 1976 | https://conductscience.org/library/papers/989885 | PubMed |
| 3 | 945,489 | Studies with bromocriptine. Part 1. "On-off" phenomena. | Neurology | 1976 | https://conductscience.org/library/papers/945489 | PubMed |
| 4 | 4,425,916 | Bromocriptine in Parkinsonism. | Br Med J | 1974 | https://conductscience.org/library/papers/4425916 | PubMed |
| 5 | 4,154,991 | Long-lasting anti-tremor induced by 2-Br-alpha-ergocryptine in monkeys. | J Pharm Pharmacol | 1974 | https://conductscience.org/library/papers/4154991 | PubMed |
| 6 | 166,332 | Studies on the antiparkinsonism efficacy of lergotrile. | Neurology | 1975 | https://conductscience.org/library/papers/166332 | PubMed |
| 7 | 4,146,398 | Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. | J Pharm Pharmacol | 1973 | https://conductscience.org/library/papers/4146398 | PubMed |
| 8 | 59,850 | Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. | Lancet | 1976 | https://conductscience.org/library/papers/59850 | PubMed |
| 9 | 181,692 | Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. | Neurology | 1976 | https://conductscience.org/library/papers/181692 | PubMed |
| 10 | 167,567 | Modification of involuntary movements by centrally acting drugs. | Adv Neurol | 1975 | https://conductscience.org/library/papers/167567 | PubMed |
| 11 | 817,221 | The antiparkinsonian efficacy of bromocriptine. | Neurology | 1976 | https://conductscience.org/library/papers/817221 | PubMed |
| 12 | 772,175 | Bromocriptine treatment in Parkinson's disease. | J Neurol Neurosurg Psychiatry | 1976 | https://conductscience.org/library/papers/772175 | PubMed |
| 13 | 773,080 | Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial. | Acta Neurol Scand | 1976 | https://conductscience.org/library/papers/773080 | PubMed |
| 14 | 778,655 | Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism. | Neurology | 1976 | https://conductscience.org/library/papers/778655 | PubMed |
| 15 | 5,104,054 | Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-alpha-Ergokryptine (CB 154). | Experientia | 1971 | https://conductscience.org/library/papers/5104054 | PubMed |
| 16 | 5,752,992 | [2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat]. | Experientia | 1968 | https://conductscience.org/library/papers/5752992 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 6,862,842 | Bromocriptine--lisuride cross tolerance. | Ital J Neurol Sci | 1983 | https://conductscience.org/library/papers/6862842 | PubMed |
| 6,435,991 | Anti-parkinsonian drugs today. | Drugs | 1984 | https://conductscience.org/library/papers/6435991 | PubMed |
| 6,180,142 | Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085. | J Neurol | 1982 | https://conductscience.org/library/papers/6180142 | PubMed |
| 3,063,495 | Therapeutic applications of bromocriptine in endocrine and neurological diseases. | Drugs | 1988 | https://conductscience.org/library/papers/3063495 | PubMed |
| 39,308 | Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy. | Psychopharmacology (Berl) | 1979 | https://conductscience.org/library/papers/39308 | PubMed |
| 37,066 | Bromocriptine in the treatment of parkinsonism. | Drugs | 1979 | https://conductscience.org/library/papers/37066 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/591982
GET https://conductscience.org/api/papers/v1/591982/authors